做多
ADTX Breakout Stock Alert Update
BREAKOUT STOCK ALERT UPDATE
ADTX - ADiTx Therapeutics, Inc. - Common Stock
Initial Alert Price: $2.1
Price High: $6.73
% Gains/Losses: 220.48%
(+201% More Than Expected)
Potential Stop Loss: $6.3935
ADTX hit $6.73 providing a 180.42% Return on Investment from our initial trade alert on December 22nd, 2020 due to the release date being set for the AditxtScore Platform Immune Monitoring Platform on Feb. 1st, 2020. The initial application of the platform will be AditxtScore for Covid-19, which has been designed to provide a more complete assessment of an individual's infection and immunity status with respect to the SARS-CoV-2 virus. We're currently seeing some healthy pullback but expect this to continue to run as the stock is showing signs of reversing on the lower timeframes as of this message. Keep a close on eye on this moving forward and look forward for our Exit Strategy Alert if we see one fit for this trade at this time. #Breakout #Stocks #Trading #Investing #Alerts #StockMarket #Daily #News #Today
ADTX - ADiTx Therapeutics, Inc. - Common StockInitial Alert Price: $2.1
Price High: $6.73
% Gains/Losses: 220.48%
(+201% More Than Expected)
Potential Stop Loss: $6.3935
ADTX hit $6.73 providing a 180.42% Return on Investment from our initial trade alert on December 22nd, 2020 due to the release date being set for the AditxtScore Platform Immune Monitoring Platform on Feb. 1st, 2020. The initial application of the platform will be AditxtScore for Covid-19, which has been designed to provide a more complete assessment of an individual's infection and immunity status with respect to the SARS-CoV-2 virus. We're currently seeing some healthy pullback but expect this to continue to run as the stock is showing signs of reversing on the lower timeframes as of this message. Keep a close on eye on this moving forward and look forward for our Exit Strategy Alert if we see one fit for this trade at this time. #Breakout #Stocks #Trading #Investing #Alerts #StockMarket #Daily #News #Today
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。